Brokerages Set Eidos Therapeutics Inc (NASDAQ:EIDX) Target Price at $30.50
Eidos Therapeutics Inc (NASDAQ:EIDX) has been assigned a consensus rating of “Buy” from the nine research firms that are presently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and six have issued a buy rating on the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $30.50.
A number of analysts have commented on the company. Zacks Investment Research cut ExlService from a “hold” rating to a “sell” rating in a research report on Wednesday, July 10th. BMO Capital Markets lowered Capital Power from an “outperform” rating to a “market perform” rating in a research note on Wednesday, May 8th. Finally, BTIG Research set a $14.00 price objective on ARBOR RLTY TR I/SH and gave the company a “buy” rating in a research note on Wednesday, April 17th.
Shares of NASDAQ EIDX traded up $0.36 during trading on Wednesday, hitting $40.33. 6,694 shares of the company traded hands, compared to its average volume of 216,904. Eidos Therapeutics has a 1 year low of $8.89 and a 1 year high of $40.52. The stock has a 50-day moving average of $31.66. The company has a market cap of $1.47 billion and a price-to-earnings ratio of -21.70. The company has a debt-to-equity ratio of 0.01, a current ratio of 19.04 and a quick ratio of 19.04.
In related news, insider Uma Sinha sold 5,000 shares of the firm’s stock in a transaction that occurred on Thursday, May 23rd. The stock was sold at an average price of $27.28, for a total transaction of $136,400.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, major shareholder Bridgebio Pharma, Inc. purchased 1,103,848 shares of the firm’s stock in a transaction that occurred on Friday, May 24th. The shares were acquired at an average cost of $25.93 per share, with a total value of $28,622,778.64. The disclosure for this purchase can be found here. Insiders have sold a total of 57,000 shares of company stock valued at $1,705,340 over the last three months.
Several hedge funds have recently modified their holdings of EIDX. BlackRock Inc. increased its holdings in Eidos Therapeutics by 57.9% during the 4th quarter. BlackRock Inc. now owns 1,149,364 shares of the company’s stock worth $15,814,000 after purchasing an additional 421,666 shares during the period. Candriam Luxembourg S.C.A. increased its holdings in Eidos Therapeutics by 193.1% during the 1st quarter. Candriam Luxembourg S.C.A. now owns 425,000 shares of the company’s stock worth $9,967,000 after purchasing an additional 280,000 shares during the period. Hillhouse Capital Advisors Ltd. purchased a new position in Eidos Therapeutics during the 4th quarter worth $2,458,000. Opaleye Management Inc. purchased a new position in Eidos Therapeutics during the 4th quarter worth $1,926,000. Finally, Geode Capital Management LLC increased its holdings in Eidos Therapeutics by 155.2% during the 4th quarter. Geode Capital Management LLC now owns 80,021 shares of the company’s stock worth $1,101,000 after purchasing an additional 48,659 shares during the period. 34.01% of the stock is owned by hedge funds and other institutional investors.
Eidos Therapeutics Company Profile
Eidos Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on developing drugs to treat diseases caused by transthyretin (TTR) amyloidosis (ATTR). It is developing AG10, an orally-administered small molecule designed to stabilize tetrameric TTR, thereby halting at its outset the series of molecular events that give rise to ATTR.
Receive News & Ratings for Eidos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eidos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.